
There Are Two New Drugs to Treat Gonorrhea
The FDA approved two new drugs to treat gonorrhea The new drugs—gepotidacin and zoliflodacin—are both new kinds of antibiotics and represent the first completely new treatment options in over thirty years.
Bacterial vaginosis (BV) is a common gynecological infection. BV is caused when the “good” and “bad” bacteria that naturally live in the vagina become out of balance. Some women will have no symptoms of a BV infection, but others may experience itching, irritation, and abnormal discharge. BV is not a sexually transmitted infection (STI), but when left untreated it can increase the risk of contracting other STIs including chlamydia, HPV, and HIV.
A new study from Albert Einstein College of Medicine, Roswell Park Comprehensive Cancer Center, and the Icahn School of Medicine at Mount Sinai looked at the vaginal microbiome of young women to try to better understand the link between BV and STIs. It found that there are two distinct types of BV infection, one of which increases the risk of chlamydia infection. The researchers think this discovery could one day change how we screen for and treat BV.
Researchers recruited 560 adolescent and young adult women who were Black or Latina. Both BV and chlamydia are more common among women in these communities. They took samples of vaginal and cervical fluid from participants who did not have chlamydia, from those who had a current infection, and from those who had recently been treated with antibiotics. DNA sequencing of the samples allowed them to identify the two types of BV.
Dr. Robert Burk, who served as co-lead on this study, explained, “This research shows that specific changes in the cervicovaginal microbiome set the stage for chlamydia. And it shows that targeting treatment against the more-dangerous BV subtype could potentially prevent many women from developing chlamydia, which is particularly prevalent in historically underserved communities.”
Health care providers don’t yet have the technology to test for which type of BV a person has, but Burk and his colleagues envision a future where there is more regular testing for BV and high-risk types are treated immediately. “We can now determine which BV cases are most worrisome and should be closely monitored. Detecting and treating these infections could substantially reduce the incidence of chlamydia and its serious consequences including pelvic inflammatory disease, infertility, and miscarriage,” Burk explained.
More research has to be done, however, before this can become the standard for testing and treatment.
In the meantime, it’s important for women to see a provider whenever they have symptoms of vaginal itching, burning, or irritation. It could be a yeast infection, BV, or an STI such as chlamydia or gonorrhea. Getting diagnosed and treated as soon as possible can relieve symptoms, prevent long-term complications, and help stop the spread of STIs.
It’s also important that people who are sexually active get regularly tested for STIs like chlamydia or gonorrhea because they often have no symptoms. The CDC recommends, for example, that sexually active young women under 25 get screened for chlamydia at least once each year.

The FDA approved two new drugs to treat gonorrhea The new drugs—gepotidacin and zoliflodacin—are both new kinds of antibiotics and represent the first completely new treatment options in over thirty years.

The American Cancer Society (ACS) released new recommendations for cervical cancer screening that focus on HPV testing and approve the use of self-collected samples. The recommendations also clarify the age at which screening should start and stop.

Public health officials in England announced that they have identified a new combined type of mpox. Tests show the virus was a unique mix of the two known types of mpox and experts are concerned about what this means for future spread of the virus.

A committee that advises the Centers for Disease Control and Prevention (CDC) made an alarming change to the recommendations for the hepatitis B vaccine that will leave some infants unprotected.

The Centers for Disease Control and Prevention (CDC) recently made striking changes to its online information about the connection between vaccines and autism that put the agency on the wrong side of science.

A new report from the World Health Organization (WHO) warns of rising levels of drug-resistant gonorrhea. The data comes from reported cases of gonorrhea in 12 countries across five WHO regions.

We’ve known for years that the HPV vaccine works. Now new research shows that widespread vaccination even protects those who haven’t gotten the shot. This study proves that it is possible to reach herd immunity for HPV.

A more serious type of mpox may be spreading California. Three people in the state were hospitalized with the virus.
ASHA believes that all people have the right to the information and services that will help them to have optimum sexual health. We envision a time when stigma is no longer associated with sexual health and our nation is united in its belief that sexuality is a normal, healthy, and positive aspect of human life.
ABOUT
GET INVOLVED
ASHA WEBSITES
GET HELP
© 2025 American Sexual Health Association